LACC with low ERCC1 expression has better survival

LACC with low ERCC1 expression has better survival | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article LACC with low ERCC1 expression has better survival Zhang Zhongxin, Chen Wei, Qin Junwei, Ge Meiye, Li Baopeng This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5517183/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Aims and background . To investigate the ERCCl protein in locally advanced cervical cancer tissues and its relationship with the efficacy of radiotherapy and chemotherapy. Methods and study design . Immunohistochemistry was used to detect ERCCl protein in 74 locally advanced cervical cancer tissues treated with intensity-modulated conformal radiotherapy. According to the strength of immune response, they were divided into a high expression group of 32 cases and a low expression group of 42 cases; During radiotherapy, cisplatin 40mg/m2/week is synchronized. Analyze the relationship between ERCCl protein expression status and the clinical pathological characteristics and prognosis of patients. Result . The total effective rate CR+PR of high expression of ERCC1 protein was 84.37% (27/32), while the CR+PR of low expression of ERCC1 was 88.10% (37/42), with no statistically significant difference (χ2=0.016, p=0.901). ERCC1 protein expression was not related to age, FIGO stage, pathological type, differentiation degree, lymph node metastasis, or A point dose (χ 2=3.094, 2.250, 0.002, 0.301, 0.360, 0.604, all p>0.05), but was related to recurrence and metastasis (χ2=4.160, 4.142, p<0.05). The 5-year survival rates of the two group were 34.38% and 78.57%, respectively, with a significant difference (χ2=3.965, p=0.046). Conclusion . The group with high expression of ERCCl protein is more prone to local recurrence and distant metastasis than the group with low expression of ERCCl protein. The expression status of ERCCl protein may become one of the biological indicators for predicting the prognosis of cervical cancer, which has certain guiding significance for the judgment of patient prognosis. Localized advanced cervical cancer Nucleotide excision repair genes (ERCCl) Synchronous radiotherapy and chemotherapy Immunohistochemistry Full Text Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5517183","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":391411392,"identity":"0cc428c3-cc62-4380-a519-f2f9d1579c1f","order_by":0,"name":"Zhang Zhongxin","email":"","orcid":"","institution":"Qingdao Municipal Hospital","correspondingAuthor":false,"prefix":"","firstName":"Zhang","middleName":"","lastName":"Zhongxin","suffix":""},{"id":391411393,"identity":"c0889829-6a13-4131-baa2-7364e06509fa","order_by":1,"name":"Chen Wei","email":"","orcid":"","institution":"Qingdao Municipal Hospital","correspondingAuthor":false,"prefix":"","firstName":"Chen","middleName":"","lastName":"Wei","suffix":""},{"id":391411394,"identity":"a57a4832-62cf-457c-9382-2e98cb62e772","order_by":2,"name":"Qin Junwei","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA7klEQVRIie3RsYrCMBjA8ZSAU2xWA8K9wlcKFaHoq6QUOh3c2jEg9Bkqgo/h/IWCLkXXgA55hHa77S6Iyx1ne6ND/gSSIT+SEEJ8vleMkgDdBG6FKCFlnKtRQh5kkllbFnNR4/hBD8LiyLZNCkoObw9PU8S+SmO+U8ksqy4MCAZd//6ciCaUelsVyeyGhSNXtqCKiu3hOYGGueHuQ4w83slS4YROx8lX+mayypEzA5T/ISUmYHIKssVxIhzRdZnHkSkCK8uciVpvBt8SXtrIdrCK9uaj05+wWnO+0V0/QO6f8qtADez/m/h8Pp/vZ99MJVoSmqab6gAAAABJRU5ErkJggg==","orcid":"","institution":"Qingdao Municipal Hospital","correspondingAuthor":true,"prefix":"","firstName":"Qin","middleName":"","lastName":"Junwei","suffix":""},{"id":391411397,"identity":"f3836000-29fc-4b43-b6ab-9b7c42839e4e","order_by":3,"name":"Ge Meiye","email":"","orcid":"","institution":"Qingdao Municipal Hospital","correspondingAuthor":false,"prefix":"","firstName":"Ge","middleName":"","lastName":"Meiye","suffix":""},{"id":391411398,"identity":"cecfdf5c-be9e-4fdd-90e9-c51c6193f7c0","order_by":4,"name":"Li Baopeng","email":"","orcid":"","institution":"Qingdao West Coast New Area People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Li","middleName":"","lastName":"Baopeng","suffix":""}],"badges":[],"createdAt":"2024-11-25 05:53:29","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5517183/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5517183/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":80310706,"identity":"665d0f1c-d7c0-4dfc-a7a7-2e23050d43e7","added_by":"auto","created_at":"2025-04-10 11:16:42","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":536521,"visible":true,"origin":"","legend":"","description":"","filename":"LACCwithlowERCC1expressionhasbettersurvival.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5517183/v1_covered_488d2212-b07e-4cba-a500-8937ec0a0c5d.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"LACC with low ERCC1 expression has better survival","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Localized advanced cervical cancer, Nucleotide excision repair genes (ERCCl), Synchronous radiotherapy and chemotherapy, Immunohistochemistry","lastPublishedDoi":"10.21203/rs.3.rs-5517183/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5517183/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eAims and background\u003c/strong\u003e. To investigate the ERCCl protein in locally advanced cervical cancer tissues and its relationship with the efficacy of radiotherapy and chemotherapy.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods and study design\u003c/strong\u003e. Immunohistochemistry was used to detect ERCCl protein in 74 locally advanced cervical cancer tissues treated with intensity-modulated conformal radiotherapy. According to the strength of immune response, they were divided into a high expression group of 32 cases and a low expression group of 42 cases; During radiotherapy, cisplatin 40mg/m2/week is synchronized. Analyze the relationship between ERCCl protein expression status and the clinical pathological characteristics and prognosis of patients.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResult\u003c/strong\u003e. The total effective rate CR+PR of high expression of ERCC1 protein was 84.37% (27/32), while the CR+PR of low expression of ERCC1 was 88.10% (37/42), with no statistically significant difference (χ2=0.016, p=0.901). ERCC1 protein expression was not related to age, FIGO stage, pathological type, differentiation degree, lymph node metastasis, or A point dose (χ 2=3.094, 2.250, 0.002, 0.301, 0.360, 0.604, all p\u0026gt;0.05), but was related to recurrence and metastasis (χ2=4.160, 4.142, p\u0026lt;0.05). The 5-year survival rates of the two group were 34.38% and 78.57%, respectively, with a significant difference (χ2=3.965, p=0.046).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e. The group with high expression of ERCCl protein is more prone to local recurrence and distant metastasis than the group with low expression of ERCCl protein. The expression status of ERCCl protein may become one of the biological indicators for predicting the prognosis of cervical cancer, which has certain guiding significance for the judgment of patient prognosis.\u003c/p\u003e","manuscriptTitle":"LACC with low ERCC1 expression has better survival","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-12-19 07:56:30","doi":"10.21203/rs.3.rs-5517183/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"bf334994-c319-4686-8c59-d984e1b764e7","owner":[],"postedDate":"December 19th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-04-10T11:08:34+00:00","versionOfRecord":[],"versionCreatedAt":"2024-12-19 07:56:30","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-5517183","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5517183","identity":"rs-5517183","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}